Élodie Pastural1, Shelly A McNeil2, Donna MacKinnon-Cameron3, Lingyun Ye3, Joanne M Langley4, Robert Stewart5, Luis H Martin1, Gregory J Hurley6, Sanaz Salehi6, Thomas A Penfound6, Scott Halperin4, James B Dale6. 1. Pan-Provincial Vaccine Enterprise Inc. (PREVENT), Saskatoon, Saskatchewan, Canada. 2. Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada; Division of Infectious Diseases, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. Electronic address: Shelly.McNeil@nshealth.ca. 3. Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada. 4. Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada; Division of Infectious Diseases, Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada. 5. Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 6. Division of Infectious Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Abstract
BACKGROUND: Streptococcus pyogenes (group A Streptococcus, Strep A) is a widespread pathogen that continues to pose a significant threat to human health. The development of a Strep A vaccine remains an unmet global health need. One of the major vaccine strategies is the use of M protein, which is a primary virulence determinant and protective antigen. Multivalent recombinant M protein vaccines are being developed with N-terminal M peptides that contain opsonic epitopes but do not contain human tissue cross-reactive epitopes. METHODS: We completed a Phase I trial of a recombinant 30-valent M protein-based Strep A vaccine (Strep A vaccine, StreptAnova™) comprised of four recombinant proteins containing N-terminal peptides from 30 M proteins of common pharyngitis and invasive and/or rheumatogenic serotypes, adjuvanted withaluminum hydroxide. The trial was observer-blinded and randomized in a 2:1 ratio for intramuscular administration of Strep A vaccine or an alum-based comparator in healthy adult volunteers, at 0, 30 and 180 days. Primary outcome measures were assessments of safety, including assays for antibodies that cross-reacted with host tissues, and immunogenicity assessed by ELISA with the individual vaccine peptides and by opsonophagocytic killing (OPK) assays in human blood. RESULTS:Twenty-three Strep A-vaccinated participants and 13 controls completed the study. The Strep A vaccine was well-tolerated and there was no clinical evidence of autoimmunity and no laboratory evidence of tissue cross-reactive antibodies. The vaccine was immunogenic and elicited significant increases in geometric mean antibody levels to 24 of the 30 component M antigens by ELISA. Vaccine-induced OPK activity was observed against selected M types of Strep A in vaccinated participants that seroconverted to specific M peptides. CONCLUSION: The Strep A vaccine was well tolerated and immunogenic in healthy adults, providing strong support for further clinical development. [ClinicalTrials.gov NCT02564237].
RCT Entities:
BACKGROUND:Streptococcus pyogenes (group A Streptococcus, Strep A) is a widespread pathogen that continues to pose a significant threat to human health. The development of a Strep A vaccine remains an unmet global health need. One of the major vaccine strategies is the use of M protein, which is a primary virulence determinant and protective antigen. Multivalent recombinant M protein vaccines are being developed with N-terminal M peptides that contain opsonic epitopes but do not contain human tissue cross-reactive epitopes. METHODS: We completed a Phase I trial of a recombinant 30-valent M protein-based Strep A vaccine (Strep A vaccine, StreptAnova™) comprised of four recombinant proteins containing N-terminal peptides from 30 M proteins of common pharyngitis and invasive and/or rheumatogenic serotypes, adjuvanted with aluminum hydroxide. The trial was observer-blinded and randomized in a 2:1 ratio for intramuscular administration of Strep A vaccine or an alum-based comparator in healthy adult volunteers, at 0, 30 and 180 days. Primary outcome measures were assessments of safety, including assays for antibodies that cross-reacted with host tissues, and immunogenicity assessed by ELISA with the individual vaccine peptides and by opsonophagocytic killing (OPK) assays in human blood. RESULTS: Twenty-three Strep A-vaccinated participants and 13 controls completed the study. The Strep A vaccine was well-tolerated and there was no clinical evidence of autoimmunity and no laboratory evidence of tissue cross-reactive antibodies. The vaccine was immunogenic and elicited significant increases in geometric mean antibody levels to 24 of the 30 component M antigens by ELISA. Vaccine-induced OPK activity was observed against selected M types of Strep A in vaccinated participants that seroconverted to specific M peptides. CONCLUSION: The Strep A vaccine was well tolerated and immunogenic in healthy adults, providing strong support for further clinical development. [ClinicalTrials.gov NCT02564237].
Keywords:
Bacterial vaccines; Bactericidal activity; Group A Streptococcus; M protein; Multivalent vaccine; Opsonophagocytosis; Phase I clinical trial; Strep A vaccine; StreptAnova™; Streptococcal vaccines; Streptococcus pyogenes
Authors: Jamie-Lee S Mills; Cesar M Jayashi Flores; Manisha Pandey; Michael F Good; Simone Reynolds; Christine Wun; Ainslie Calcutt; S Ben Baker; Senthil Murugappan; Alexandra C I Depelsenaire; Jessica Dooley; Paul V Fahey; Angus H Forster Journal: NPJ Vaccines Date: 2020-08-07 Impact factor: 7.344
Authors: Jay A Spencer; Tom Penfound; Sanaz Salehi; Michelle P Aranha; Lauren E Wade; Rupesh Agarwal; Jeremy C Smith; James B Dale; Jerome Baudry Journal: Vaccine Date: 2021-02-26 Impact factor: 3.641
Authors: Yuan Li; Samuel Dominguez; Srinivas A Nanduri; Joy Rivers; Saundra Mathis; Zhongya Li; Lesley McGee; Sopio Chochua; Benjamin J Metcalf; Chris A Van Beneden; Bernard Beall; Lisa Miller Journal: J Infect Dis Date: 2022-05-16 Impact factor: 7.759
Authors: Yuan Li; Joy Rivers; Saundra Mathis; Zhongya Li; Srinivasan Velusamy; Srinivas A Nanduri; Chris A Van Beneden; Paula Snippes-Vagnone; Ruth Lynfield; Lesley McGee; Sopio Chochua; Benjamin J Metcalf; Bernard Beall Journal: Front Microbiol Date: 2020-07-24 Impact factor: 5.640
Authors: Michelle P Aranha; Thomas A Penfound; Sanaz Salehi; Anne Botteaux; Pierre Smeesters; James B Dale; Jeremy C Smith Journal: J Immunol Date: 2021-08-02 Impact factor: 5.426